Drug intelligence / Profile preview

NT102

Development stage: Preclinical
Lead developer: Neuroene Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

NT102 is a vitamin K analogue developed by Neuroene Therapeutics. It is designed for the treatment of **Dravet syndrome**, a rare form of epilepsy characterized by severe seizures and developmental delays. NT102 has shown "excellent protection" against seizures in animal models, particularly in Dravet syndrome. It is well-tolerated and orally bioavailable with good brain penetration, which is crucial for therapies targeting neurological conditions. NT102 has been granted orphan drug designation by the FDA for its potential in treating Dravet syndrome.

Other names: NT-102NT102NT 102

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on NT102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT102.

Explore the full profile